Investing.com - Financial Markets Worldwide
🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Chimeric Therapeutics (ASX: CHM) shares welcome additional positive preclinical data for CHM 1301

Published 28/11/2023, 10:30 pm
Chimeric Therapeutics (ASX: CHM) shares welcome additional positive preclinical data for CHM 1301

Highlights

  • Chimeric is advancing CHM 1301 program to the next stage of preclinical development.
  • CHM 1301 is a next generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy.
  • The therapy demonstrated highly promising efficacy in preclinical studies of in vitro models of human ovarian cancer and pancreatic cancer.
  • CHM shares charged higher by 7%.

Chimeric Therapeutics Limited (ASX: CHM) shares gained over 7% on 28 November 2023 as the company announced additional information on its earlier update focused on positive in vitro data for CHM 1301.

The next generation CLTX CAR NK cell therapy program is entering the next phase of preclinical development. Under the study, the company plans to use armoured NK cell platform (CHM 0301) that was recently developed.

The study would aim to boost cell potency and resistance against the immunosuppressive solid tumour microenvironment.

Read more on Kalkine Media

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.